Supriya Lifescience Ltd has announced an earnings call scheduled for November 13, 2025, at 11:00 AM IST. This call will focus on the unaudited financial results for the quarter and half-year ending September 30, 2025. The company, based in Mumbai, aims to discuss its operational and financial performance during this period, providing valuable insights for investors and stakeholders. The call will be accessible via a pre-registration link, and a detailed investor presentation will be shared with the exchanges as part of the disclosure requirements mandated by SEBI.

The earnings call will feature key executives, including Dr. Satish Wagh, Executive Chairman & Whole-Time Director, and Dr. Saloni Wagh, Managing Director, along with Chief Financial Officer Mr. Krishna Raghunathan. Participants can join the call using various access numbers, including primary and secondary lines for different regions such as Hong Kong, Singapore, the USA, and the UK. This initiative demonstrates Supriya Lifescience’s commitment to transparency and proactive communication with its investors, as the company is recognized as a government-approved export house.

Investors and analysts are encouraged to participate in this call to gain insights into Supriya Lifescience’s performance and strategic direction. With the NSE symbol SUPRIYA and the BSE scrip code 543434, the company continues to build its reputation in the pharmaceutical sector by maintaining robust communication practices. As the earnings call approaches, stakeholders are advised to prepare for discussions that could significantly impact their investment decisions regarding the company’s future trajectory.